Market closedADR
Pharming Group/$PHAR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pharming Group
Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.
Ticker
$PHAR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
404
Website
Pharming Group Metrics
BasicAdvanced
$553M
-
-$0.02
0.60
-
Price and volume
Market cap
$553M
Beta
0.6
52-week high
$9.65
52-week low
$7.50
Average daily volume
6.3K
Financial strength
Current ratio
3.773
Quick ratio
2.955
Long term debt to equity
47.553
Total debt to equity
50.806
Interest coverage (TTM)
-0.41%
Management effectiveness
Return on assets (TTM)
-1.25%
Return on equity (TTM)
-5.00%
Valuation
Price to revenue (TTM)
18.41
Price to book
2.16
Price to tangible book (TTM)
2.98
Price to free cash flow (TTM)
-2,111.946
Growth
Revenue change (TTM)
21.15%
Earnings per share change (TTM)
-0.34%
3-year revenue growth (CAGR)
14.33%
3-year earnings per share growth (CAGR)
-11.39%
Pharming Group News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Pharming Group stock?
Pharming Group (PHAR) has a market cap of $553M as of April 23, 2025.
What is the P/E ratio for Pharming Group stock?
The price to earnings (P/E) ratio for Pharming Group (PHAR) stock is 0 as of April 23, 2025.
Does Pharming Group stock pay dividends?
No, Pharming Group (PHAR) stock does not pay dividends to its shareholders as of April 23, 2025.
When is the next Pharming Group dividend payment date?
Pharming Group (PHAR) stock does not pay dividends to its shareholders.
What is the beta indicator for Pharming Group?
Pharming Group (PHAR) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.